The potent effect of ATRA to prevent acquisition of BCR-ABL mutation shown in the present study suggests that ATRA could be a simple and effective agent to use in combination with tyrosine kinase inhibitors to prevent acquisition of resistance and improve outcomes of CML, particularly in the advanced phases. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.